Christopher Richard Anzalone serves as Chief Executive Officer of ARROWHEAD PHARMACEUTICALS, INC. (ARWR). Anzalone has reported 3 insider filings with the SEC since 2024. The most recent filing was in December 2025.
Every role Christopher Richard Anzalone has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)3 filingsUpdated Aug 30, 2026
Christopher Richard Anzalone is Chief Executive Officer, Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR). 3 SEC Form 4 filings on record going back to 2024, most recently on 16 December 2025. Most recent open-market trade: sold $219K of ARWR on 16 December 2025. Lifetime open-market sales: $13.16M.
Every recent SEC Form 4 transaction Christopher Richard Anzalone has reported, most recent first.
InsiderAlpha's records for Christopher Richard Anzalone go back to 2024: 3 primary Form 4 filings, an average of 1.0 per year. 5 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Christopher Richard Anzalone files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Christopher Richard Anzalone is a corporate insider, tracked as Chief Executive Officer, Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 16 December 2025, one of 3 filings going back to 2024.
Recorded transactions: 0 open-market purchases and 16 open-market sales ($13.16M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$ARWR ARROWHEAD PHARMACEUTICALS, INC.1.3K shares @ $65.77$86K